Drug Trial Radar · NCT04917302
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Oct 13, 2020
Primary completion
Nov 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- China Medical University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ministry of Science and Technology, Taiwan
- First posted
- Jun 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with chronic schizophrenia. In addition, several drugs with anti-inflammatory properties have been tested in clinical trials for the treatment of schizophrenia too. Whether combined treatment of an NMDA-enhancing agent and a drug with anti-inflammatory property can be better than an NMDA-enhancing agent alone deserves study.
Conditions
- Schizophrenia
Interventions
NMDAE plus AIFADrug
Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of schizophrenia.
NMDAE plus Placebo CapDrug
Use of an NMDA enhancer plus placebo as a comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change of Positive and Negative Syndrome Scale (PANSS)Time frame: week 0, 2, 4, 6, 9, 12]
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Psychiatry, China Medical University Hospital
Taichung, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.